Xponance’s bluebird bio BLUE Stock Holding History

Xponance’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-592	Closed	-$6.15K	–	1447
2024 Q3	$6.15K	Hold	592	–	–	﹤0.01%	1389
2024 Q2	$11.7K	Hold	592	–	–	﹤0.01%	1316
2024 Q1	$15.2K	Buy	+592	New	+$15.2K	﹤0.01%	1301

Other funds holding BLUE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Xponance's BLUE Position: Q4 2024 in Review

Xponance sold out of bluebird bio (BLUE) in Q4 2024, closing a stake of 592 shares — an estimated $6.15K sold.

Xponance first reported a position in BLUE in Q1 2024 and held it in 3 quarters. The position peaked at $15.2K in Q1 2024. 83 funds tracked by Wall St. Rank hold BLUE as of Q4 2024.

Xponance reported no remaining bluebird bio position as of Q4 2024 after selling out during the quarter.
Xponance sold 592 bluebird bio shares in Q4 2024, an estimated $6.15K.
Xponance first reported a position in bluebird bio in Q1 2024 and held it in 3 quarters.
Xponance's bluebird bio position peaked at $15.2K in Q1 2024.
83 funds tracked by Wall St. Rank held bluebird bio as of Q4 2024.

Based on Xponance's 13F filing for Q4 2024, filed 11 Feb 2025.